Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF1R | P08069 | 19/20 | 0.46 |
| ▸ | CDK1 | P06493 | 1/20 | 0.45 |
| ▸ | CDK2 | P24941 | 1/20 | 0.45 |
| ▸ | CDK8 | P49336 | 1/20 | 0.45 |
| ▸ | CDK7 | P50613 | 1/20 | 0.45 |
| ▸ | CDK9 | P50750 | 1/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27275136 | 1.00 | IGF1R (0.46) | IGF1RCDK1CDK2CDK8CDK7 | |
| SCHEMBL27275089 | 0.94 | TBK1 (0.41) | IGF1RCDK1CDK2CDK8CDK7 | |
| SCHEMBL29754166 | 0.94 | TBK1 (0.41) | IGF1RCDK1CDK2CDK8CDK7 | |
| SCHEMBL29754262 | 0.93 | MAP3K14 (0.40) | IGF1RCDK1CDK2CDK8CDK7 | |
| SCHEMBL22546065 | 0.93 | MAP3K14 (0.40) | IGF1RCDK1CDK2CDK8CDK7 | |
| SCHEMBL27275040 | 0.92 | IGF1R (0.47) | IGF1RCDK1CDK2CDK8CDK7 | |
| SCHEMBL29754214 | 0.92 | TBK1 (0.43) | CDK2IRAK4 | |
| SCHEMBL22529468 | 0.92 | TBK1 (0.43) | CDK2IRAK4 | |
| SCHEMBL22544655 | 0.92 | IRAK4 (0.47) | CDK2IRAK4 | |
| SCHEMBL29754267 | 0.92 | IRAK4 (0.47) | CDK2IRAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220259182-A1 | BENZETHERS AND ANILINES OF PYRAZOLYL-AMINO-PYRIMIDINYL DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF | LYNK PHARMACEUTICALS CO. LTD. (CN) | 2022-08-18 | — | — | US | claimed |
| CN-118702683-A | Phenyl ethers and anilines of pyrazolyl-amino-pyrimidinyl derivatives, compositions and methods thereof | 凌科药业(杭州)有限公司 | 2024-09-27 | — | — | CN | disclosed |
| US-12024503-B2 | Benzethers and anilines of pyrazolyl-amino-pyrimidinyl derivatives, and compositions and methods thereof | LYNK PHARMACEUTICALS CO. LTD. (CN) | 2024-07-02 | — | — | US | disclosed |
| CN-113993861-B | Phenyl ethers and anilines of pyrazolyl-amino-pyrimidinyl derivatives, compositions and methods thereof | 凌科药业(杭州)有限公司 | 2024-05-14 | — | — | CN | disclosed |
| US-20240083882-A1 | BENZETHERS AND ANILINES OF PYRAZOLYL-AMINO-PYRIMIDINYL DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF | LYNK PHARMACEUTICALS CO. LTD. (CN) | 2024-03-14 | — | — | US | disclosed |
| US-20220259182-A1 | BENZETHERS AND ANILINES OF PYRAZOLYL-AMINO-PYRIMIDINYL DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF | LYNK PHARMACEUTICALS CO. LTD. (CN) | 2022-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12024503-B2 | Benzethers and anilines of pyrazolyl-amino-pyrimidinyl derivatives, and compositions and methods thereof | JAK3, JAK1, JAK2 | IGF1R 3027/4885CDK1 143/4885CDK2 125/4885 |
| US-20220259182-A1 | BENZETHERS AND ANILINES OF PYRAZOLYL-AMINO-PYRIMIDINYL DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF | JAK3, JAK1, JAK2 | IGF1R 2980/4885CDK1 148/4885CDK2 128/4885 |
| US-20240083882-A1 | BENZETHERS AND ANILINES OF PYRAZOLYL-AMINO-PYRIMIDINYL DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF | JAK3, JAK1, JAK2 | IGF1R 2980/4885CDK1 148/4885CDK2 128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.